

Docket 17684 (AP)

*For fee
only***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of
Lyons et al
Customer No.: 51957
Serial No.: 10/826,843

Filed: April 15, 2004

For: **DRUG DELIVERY TO THE BACK OF
THE EYE**

Group Art Unit: 1618

Confirmation No. 2070

Examiner: Zohreh A. Fay

**RECEIVED
CENTRAL FAX CENTER**

AUG 19 2005**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mailstop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant wishes to call to the attention of the Examiner the document cited on the accompanying PTO Form 1449. No concession is made that this document is prior art, and applicant expressly reserves the right to antedate the document as may be appropriate. Applicant requests that his document be made of record in the above-identified application.


Further, submitted herewith is a Supplemental Reply Under 37 CFR § 1.111 is a request for consideration of the Supplemental Information Disclosure Statement and an authorization to charge Deposit Account 01-0885 for the fee set forth in 37 CFR 1.17 (p).

Docket 17684 (AP)

In view of the above, applicant submits that this Supplemental Information Disclosure Statement is to be considered under 37 CFR 1.97 (d).

Respectfully submitted,


Date: 8-19-05


Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson-T2-7H
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF FACSIMILE

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being faxed to the Central Fax Number 571-273-8300 on 8/19/05
by 
Bonnie Ferguson